| Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report A Palumbo, S Bringhen, MV Mateos, A Larocca, T Facon, SK Kumar, ... Blood, The Journal of the American Society of Hematology 125 (13), 2068-2074, 2015 | 838 | 2015 |
| Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple … A Palumbo, S Bringhen, D Rossi, M Cavalli, A Larocca, R Ria, M Offidani, ... Journal of Clinical Oncology 28 (34), 5101-5109, 2010 | 538 | 2010 |
| Efficacy and safety of once-weekly bortezomib in multiple myeloma patients S Bringhen, A Larocca, D Rossi, M Cavalli, M Genuardi, R Ria, S Gentili, ... Blood, The Journal of the American Society of Hematology 116 (23), 4745-4753, 2010 | 501 | 2010 |
| European Myeloma Network guidelines for the management of multiple myeloma-related complications E Terpos, M Kleber, M Engelhardt, S Zweegman, F Gay, E Kastritis, ... haematologica 100 (10), 1254, 2015 | 444 | 2015 |
| Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label … PG Richardson, A Oriol, M Beksac, AM Liberati, M Galli, F Schjesvold, ... The Lancet Oncology 20 (6), 781-794, 2019 | 389 | 2019 |
| Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients F Gay, A Larocca, P Wijermans, F Cavallo, D Rossi, R Schaafsma, ... Blood, The Journal of the American Society of Hematology 117 (11), 3025-3031, 2011 | 357 | 2011 |
| Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide A Larocca, F Cavallo, S Bringhen, F Di Raimondo, A Falanga, ... Blood, The Journal of the American Society of Hematology 119 (4), 933-939, 2012 | 349 | 2012 |
| Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data A Palumbo, S Bringhen, SK Kumar, G Lupparelli, S Usmani, A Waage, ... The lancet oncology 15 (3), 333-342, 2014 | 345 | 2014 |
| International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem … A Palumbo, SV Rajkumar, JF San Miguel, A Larocca, R Niesvizky, ... Journal of clinical oncology 32 (6), 587-600, 2014 | 325 | 2014 |
| European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma M Engelhardt, E Terpos, M Kleber, F Gay, R Wäsch, G Morgan, M Cavo, ... haematologica 99 (2), 232, 2014 | 287 | 2014 |
| Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project M D'agostino, DA Cairns, JJ Lahuerta, R Wester, U Bertsch, A Waage, ... Journal of clinical oncology 40 (29), 3406-3418, 2022 | 273 | 2022 |
| Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials S Bringhen, MV Mateos, S Zweegman, A Larocca, AP Falcone, A Oriol, ... Haematologica 98 (6), 980, 2013 | 266 | 2013 |
| Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple … A Palumbo, S Bringhen, A Larocca, D Rossi, F Di Raimondo, V Magarotto, ... Journal of Clinical Oncology 32 (7), 634-640, 2014 | 253 | 2014 |
| Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial MV Mateos, H Blacklock, F Schjesvold, A Oriol, D Simpson, A George, ... The Lancet Haematology 6 (9), e459-e469, 2019 | 251 | 2019 |
| Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial SZ Usmani, F Schjesvold, A Oriol, L Karlin, M Cavo, RM Rifkin, HA Yimer, ... The Lancet Haematology 6 (9), e448-e458, 2019 | 231 | 2019 |
| Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma A Palumbo, F Gay, F Cavallo, F Di Raimondo, A Larocca, I Hardan, ... Journal of Clinical Oncology 33 (30), 3459-3466, 2015 | 187 | 2015 |
| Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study S Bringhen, MT Petrucci, A Larocca, C Conticello, D Rossi, V Magarotto, ... Blood, The Journal of the American Society of Hematology 124 (1), 63-69, 2014 | 168 | 2014 |
| Second primary malignancies in multiple myeloma: an overview and IMWG consensus P Musto, KC Anderson, M Attal, PG Richardson, A Badros, J Hou, ... Annals of Oncology 28 (2), 228-245, 2017 | 165 | 2017 |
| European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when J Caers, L Garderet, KM Kortüm, ME O’Dwyer, NWCJ van de Donk, ... haematologica 103 (11), 1772, 2018 | 148 | 2018 |
| Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation A Larocca, G Piaggio, M Podestà, A Pitto, B Bruno, C Di Grazia, ... haematologica 91 (7), 935-940, 2006 | 142 | 2006 |
